6-Diazo-5-oxo-l-norleucine (DON) is a glutamine antagonist
with robust anticancer efficacy; however, its therapeutic potential
was hampered by its biodistribution and toxicity to normal tissues,
specifically gastrointestinal (GI) tissues. To circumvent DON’s
toxicity, we synthesized a series of tumor-targeted DON prodrugs designed
to circulate inert in plasma and preferentially activate over DON
in tumor. Our best prodrug 6 (isopropyl 2-(6-acetamido-2-(adamantane-1-carboxamido)hexanamido)-6-diazo-5-oxohexanoate)
showed stability in plasma, liver, and intestinal homogenates yet
was readily cleaved to DON in P493B lymphoma cells, exhibiting a 55-fold
enhanced tumor cell-to-plasma ratio versus that of DON and resulting
in a dose-dependent inhibition of cell proliferation. Using carboxylesterase
1 knockout mice that were shown to mimic human prodrug metabolism,
systemic administration of 6 delivered 11-fold higher
DON exposure to tumor (target tissue; AUC0–t
= 5.1 nmol h/g) versus GI tissues (toxicity tissue; AUC0–t
= 0.45 nmol h/g). In summary, these
studies describe the discovery of a glutamine antagonist prodrug that
provides selective tumor exposure.
The carbon and nitrogen components of glutamine are used for multiple biosynthetic processes by tumors. Glutamine metabolism and the therapeutic potential of glutamine antagonists (GA), however, are incompletely understood in malignant peripheral nerve sheath tumor (MPNST), an aggressive soft tissue sarcoma observed in patients with neurofibromatosis type I. We investigated glutamine dependence of MPNST using JHU395, a novel orally bioavailable GA prodrug designed to circulate inert in plasma, but permeate and release active GA within target tissues. Human MPNST cells, compared with Schwann cells derived from healthy peripheral nerve, were selectively susceptible to both glutamine deprivation and GA dose-dependent growth inhibition. In vivo, orally administered JHU395 delivered active GA to tumors with over 2-fold higher tumor-to-plasma exposure, and significantly inhibited tumor growth in a murine flank MPNST model without observed toxicity. Global metabolomics studies and stable isotopelabeled flux analyses in tumors identified multiple glutaminedependent metabolites affected, including prominent effects on purine synthesis. These data demonstrate that glutamine antagonism is a potential antitumor strategy for MPNST.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.